Abstract
Apelin agonism causes systemic vasodilatation and increased cardiac contractility in humans, and improves pulmonary arterial hypertension (PAH) in animal models. Here, the authors examined the short-term pulmonary hemodynamic effects of systemic apelin infusion in patients with PAH. In a double-blind randomized crossover study, 19 patients with PAH received intravenous (Pyr 1)apelin-13 and matched saline placebo during invasive right heart catheterization. (Pyr 1)apelin-13 infusion caused a reduction in pulmonary vascular resistance and increased cardiac output. This effect was accentuated in the subgroup of patients receiving concomitant phosphodiesterase type 5 inhibition. Apelin agonism is a novel potential therapeutic target for PAH.
Original language | English |
---|---|
Pages (from-to) | 176-186 |
Number of pages | 11 |
Journal | JACC: Basic to Translational Science |
Volume | 3 |
Issue number | 2 |
Early online date | 28 Mar 2018 |
DOIs | |
Publication status | Published - Apr 2018 |
Keywords
- apelin pulmonary hypertension
- apelin
- APJ
- human
- pulmonary arterial hypertension
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine